Search results

607 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Social care guidelines Remove Social care guidelines filter
Quality standards Remove Quality standards filter

Pegcetacoplan for previously treated paroxysmal nocturnal haemoglobinuria [ID3746]

In development [GID-TA10651] Expected publication date: 02 February 2022

Type

Technology appraisal guidance

Status

In development
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 18 August 2021

Type

Technology appraisal guidance

Status

In development
Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

In development [GID-TA10541] Expected publication date: 24 February 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]

In development [GID-TA10498] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Cenobamate for focal onset seizures in epilepsy [ID1553]

In development [GID-TA10661] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]

In development [GID-TA10639] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

In development [GID-TA10432] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]

In development [GID-TA10703] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]

In development [GID-TA10381] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]

In development [GID-TA10482] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]

In development [GID-TA10650] Expected publication date: 25 August 2021

Type

Technology appraisal guidance

Status

In development
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

In development [GID-TA10612] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]

In development [GID-TA10619] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

In development [GID-TA10624] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

In development [GID-TA10711] Expected publication date: 15 September 2021

Type

Technology appraisal guidance

Status

In development
Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

In development [GID-TA10470] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]

In development [GID-TA10626] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]

In development [GID-TAG430] Expected publication date: 03 March 2021

Type

Technology appraisal guidance

Status

In development
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]

In development [GID-TA10417] Expected publication date: 15 September 2021

Type

Technology appraisal guidance

Status

In development
Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
The Assurance Nasal Alar SpO2 Sensor (discontinued)

In development [GID-MT510] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

In development [GID-MT517] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

In development [GID-MT536] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

In development [GID-MT516] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

In development [GID-MT130] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

In development [GID-MT163] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Microthane implants for breast reconstruction or breast augmentation (discontinued)

In development [GID-MT267] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SILK artery reconstruction device (discontinued)

In development [GID-MT81] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Implantable Vagus Nerve Stimulator in Heart Failure

In development [GID-IP1145] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Electrochemotherapy for the treatment of malignant melanoma

In development [GID-IP1041] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

In development [GID-IP1151] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Extra corporeal membrane oxygenation for acute heart failure in children

In development [GID-IP1153] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Degradable surgical implant

In development [GID-IP1197] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
MRI guided focussed ultrasound for chronic pain

In development [GID-IP1043] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Ex utero intrapartum therapy for fetal obstruction

In development [GID-IP1156] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Peroral endoscopic myotomy (POEM) for achalasia

In development [GID-IP1229] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

In development [GID-IP1170] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

In development [GID-TA10418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Prostate cancer (prevention) - dutasteride [ID75]

In development [GID-TAG409] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development